EE04356B1 - aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis - Google Patents

aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis

Info

Publication number: EE04356B1
Authority: EE; Estonia
Prior art keywords: inhibitor; diabetes; treatment; pharmaceutical composition; pravastatin
Prior art date: 1998-09-17

Application number

EEP200100154A

Other languages

English (en)

Estonian (et)

Inventor

A. Robl Jeffrey

A. Biller Scott

A. Parker Rex

Jamil Haris

L. Jacobson Bruce

Kodukula Krishna

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2004-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04356(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-13 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2002-12-16 Publication of EE200100154A publication Critical patent/EE200100154A/xx

2004-10-15 Publication of EE04356B1 publication Critical patent/EE04356B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)

EEP200100154A 1998-09-17 1999-09-13 aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis EE04356B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10067798P	1998-09-17	1998-09-17
PCT/US1999/020946 WO2000015229A1 (en)	1998-09-17	1999-09-13	METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (2)

Publication Number	Publication Date
EE200100154A EE200100154A (et)	2002-12-16
EE04356B1 true EE04356B1 (et)	2004-10-15

Family

ID=22280975

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EEP200100155A EE200100155A (et)	1998-09-17	1999-09-13	Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
EEP200100154A EE04356B1 (et)	1998-09-17	1999-09-13	aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EEP200100155A EE200100155A (et)	1998-09-17	1999-09-13	Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni

Country Status (30)

Country	Link
US (1)	US20020035064A1 (tr)
EP (2)	EP1121129B1 (tr)
JP (2)	JP2002524517A (tr)
KR (2)	KR20010079842A (tr)
CN (2)	CN1317970A (tr)
AT (1)	ATE406898T1 (tr)
AU (2)	AU755563B2 (tr)
BG (2)	BG105432A (tr)
BR (2)	BR9913833A (tr)
CA (2)	CA2344309A1 (tr)
CO (2)	CO5130026A1 (tr)
CZ (2)	CZ2001965A3 (tr)
DE (1)	DE69939481D1 (tr)
EE (2)	EE200100155A (tr)
ES (1)	ES2311306T3 (tr)
GE (2)	GEP20033045B (tr)
HU (2)	HUP0104108A2 (tr)
ID (2)	ID27833A (tr)
IL (2)	IL141785A0 (tr)
LT (2)	LT4870B (tr)
LV (2)	LV12686B (tr)
NO (2)	NO20011351L (tr)
NZ (2)	NZ510207A (tr)
PE (2)	PE20001047A1 (tr)
PL (2)	PL346661A1 (tr)
SK (1)	SK3202001A3 (tr)
TR (2)	TR200100774T2 (tr)
UY (2)	UY25713A1 (tr)
WO (2)	WO2000015230A1 (tr)
ZA (2)	ZA200207433B (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999025346A1 (en) *	1997-11-19	1999-05-27	Takeda Chemical Industries, Ltd.	Novel apoptosis inhibitors
WO2000047734A1 (en) *	1999-02-12	2000-08-17	President And Fellows Of Harvard College	Inhibiting formation of atherosclerotic lesions
AU2005201289B2 (en) *	1999-02-12	2008-04-17	President And Fellows Of Harvard College	Inhibiting formation of atherosclerotic lesions
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
JP2004501066A (ja)	2000-01-28	2004-01-15	ブリストル−マイヤーズ　スクイブ　カンパニー	脂肪酸結合タンパク質のテトラヒドロピリミドンインヒビターおよび方法
CA2436854A1 (en) *	2000-11-20	2002-05-23	Bristol-Myers Squibb Company	Pyridone derivatives as ap2 inhibitors
EP1385549A2 (en) *	2001-03-12	2004-02-04	Novartis AG	Combination of nateglinide or repaglinide with at least one further antidiabetic compound
WO2003006023A1 (en)	2001-07-13	2003-01-23	Bristol-Myers Squibb Company	Pyrazinone inhibitors of fatty acid binding protein and method
AU2002322585A1 (en) *	2001-07-20	2003-03-03	Adipogenix, Inc.	Fat accumulation-modulating compounds
WO2003043624A1 (en)	2001-11-16	2003-05-30	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
EP1590336B1 (en)	2003-01-27	2010-12-01	Merck Sharp & Dohme Corp.	Substituted pyrazoles, compositions containing such compounds and methods of use
EP1620089A4 (en) *	2003-03-26	2008-12-24	Crc For Asthma Ltd	Therapeutic and prophylactic compositions and their uses
WO2004096977A2 (en) *	2003-04-30	2004-11-11	Pfizer Products Inc.	Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
DK1725234T4 (en) *	2004-03-05	2016-05-09	Univ Pennsylvania	METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
UA85884C2 (uk)	2004-06-04	2009-03-10	Мерк Енд Ко., Інк.	Похідні піразолу, композиція, що містить ці сполуки, і спосіб застосування (варіанти)
EP1841749A1 (en)	2004-09-02	2007-10-10	Metabasis Therapeutics, Inc.	Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
AU2006214164B2 (en)	2005-02-17	2010-12-09	Synta Pharmaceuticals Corp.	Isoxazole combretastin derivatives for the treatment of disorders
EP1910303A2 (en)	2005-07-26	2008-04-16	Merck & Co., Inc.	Process for synthesizing a substituted pyrazole
US20080253985A1 (en) *	2005-10-18	2008-10-16	Wisler Gerald L	Compositions for Lowering Serum Cholesterol and/or Triglycerides
WO2007143164A1 (en) *	2006-06-02	2007-12-13	San Diego State University Research Foundation	Compositions and methods for ameliorating hyperlipidemia
US20080161279A1 (en) *	2006-12-21	2008-07-03	Wisler Gerald L	Methods of Treating Obesity
JP2012508692A (ja) *	2008-11-12	2012-04-12	シェーリングコーポレイション	脂肪酸結合タンパク質（ｆａｂｐ）の阻害薬
WO2010102171A2 (en)	2009-03-05	2010-09-10	President And Fellows Of Harvard College	Secreted ap2 and methods of inhibiting same
JP6514282B2 (ja) *	2014-03-24	2019-05-15	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6223376B2 (ja)	2014-03-24	2017-11-01	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
TW201702271A (zh)	2015-04-30	2017-01-16	哈佛大學校長及研究員協會	治療代謝病症之抗－ａｐ２抗體及抗原結合劑
EA201990136A1 (ru) *	2016-06-27	2019-05-31	Президент Энд Феллоуз Оф Гарвард Колледж	Соединения, применимые для лечения нарушений обмена веществ
WO2018227200A1 (en)	2017-06-09	2018-12-13	President And Fellows Of Harvard College	Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
AU2021297465A1 (en)	2020-06-27	2023-03-02	Crescenta Biosciences	Novel cell metabolism modulating compounds and uses thereof
US12138243B2 (en)	2021-12-31	2024-11-12	Crescenta Biosciences	Antiviral use of FABP4 modulating compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2129012A1 (de)	1971-06-11	1973-01-04	Merck Patent Gmbh	Azol-derivate
FR2156486A1 (en)	1971-10-22	1973-06-01	Roussel Uclaf	Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (tr)	1974-06-07	1981-03-18
GB1507032A (en)	1974-08-06	1978-04-12	Serono Lab	2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
AU610591B2 (en)	1987-05-22	1991-05-23	E.R. Squibb & Sons, Inc.	Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) *	1989-10-27	1993-06-08	American Home Products Corporation	Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) *	1989-10-27	1991-09-13	American Home Prod	Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) *	1989-12-20	1993-11-16	Bristol-Myers Squibb Company	[2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr)	1990-06-14	1994-05-06	Bellon Laboratoires	Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) *	1990-09-11	1990-10-24	Smith Kline French Lab	Compounds
US5254576A (en) *	1992-04-03	1993-10-19	Bristol-Myers Squibb Company	Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5348969A (en) *	1992-04-03	1994-09-20	Bristol-Myers Squibb Company	Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) *	1992-04-03	1993-02-16	Bristol-Myers Squibb Company	Oxazole carboxylic acid derivatives
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
US5346701A (en)	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs
US5362879A (en) *	1993-04-15	1994-11-08	Bristol-Myers Squibb Company	4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de)	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
DE69425162T2 (de) *	1993-12-20	2000-12-21	Fujisawa Pharmaceutical Co., Ltd.	4,5-diaryloxazol-derivate
US5599770A (en)	1994-07-15	1997-02-04	Kureha Kagaku Kogyo Kabushiki Kaisha	Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
BR9508468A (pt)	1994-07-29	1997-11-25	Smithkline Beecham Plc	Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk)	1995-05-08	2003-06-16	Фармація Енд Апджон Компані	<font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6966696A (en)	1995-10-05	1997-04-28	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en)	1996-01-05	1996-03-06	Foster Wheeler Petrol Dev Ltd	Spacing bouy for flexible risers
AUPO134596A0 (en)	1996-08-01	1996-08-22	Jal Pastoral Co. Pty Ltd	Demountable article carrier for motor vehicles
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

1999
- 1999-09-13 TR TR2001/00774T patent/TR200100774T2/tr unknown
- 1999-09-13 AT AT99951438T patent/ATE406898T1/de not_active IP Right Cessation
- 1999-09-13 TR TR2001/00773T patent/TR200100773T2/tr unknown
- 1999-09-13 HU HU0104108A patent/HUP0104108A2/hu unknown
- 1999-09-13 KR KR1020017003408A patent/KR20010079842A/ko not_active Withdrawn
- 1999-09-13 JP JP2000569813A patent/JP2002524517A/ja active Pending
- 1999-09-13 GE GEAP19995860A patent/GEP20033045B/en unknown
- 1999-09-13 EP EP99951438A patent/EP1121129B1/en not_active Revoked
- 1999-09-13 JP JP2000569814A patent/JP2002524518A/ja active Pending
- 1999-09-13 PL PL99346661A patent/PL346661A1/xx unknown
- 1999-09-13 HU HU0104240A patent/HUP0104240A2/hu unknown
- 1999-09-13 AU AU61437/99A patent/AU755563B2/en not_active Ceased
- 1999-09-13 PL PL99346660A patent/PL346660A1/xx not_active Application Discontinuation
- 1999-09-13 NZ NZ510207A patent/NZ510207A/en unknown
- 1999-09-13 KR KR1020017003411A patent/KR20010075150A/ko not_active Withdrawn
- 1999-09-13 WO PCT/US1999/021069 patent/WO2000015230A1/en not_active Application Discontinuation
- 1999-09-13 IL IL14178599A patent/IL141785A0/xx unknown
- 1999-09-13 CN CN99811000A patent/CN1317970A/zh active Pending
- 1999-09-13 EE EEP200100155A patent/EE200100155A/xx unknown
- 1999-09-13 ES ES99951438T patent/ES2311306T3/es not_active Expired - Lifetime
- 1999-09-13 IL IL14178699A patent/IL141786A0/xx unknown
- 1999-09-13 CA CA002344309A patent/CA2344309A1/en not_active Abandoned
- 1999-09-13 DE DE69939481T patent/DE69939481D1/de not_active Revoked
- 1999-09-13 WO PCT/US1999/020946 patent/WO2000015229A1/en not_active Application Discontinuation
- 1999-09-13 SK SK320-2001A patent/SK3202001A3/sk unknown
- 1999-09-13 CZ CZ2001965A patent/CZ2001965A3/cs unknown
- 1999-09-13 GE GEAP19995861A patent/GEP20033044B/en unknown
- 1999-09-13 ID IDW20010626A patent/ID27833A/id unknown
- 1999-09-13 ID IDW20010624A patent/ID28450A/id unknown
- 1999-09-13 CZ CZ2001964A patent/CZ2001964A3/cs unknown
- 1999-09-13 AU AU63877/99A patent/AU754488B2/en not_active Ceased
- 1999-09-13 EE EEP200100154A patent/EE04356B1/xx not_active IP Right Cessation
- 1999-09-13 BR BR9913833-6A patent/BR9913833A/pt not_active IP Right Cessation
- 1999-09-13 CN CN99811096A patent/CN1319012A/zh active Pending
- 1999-09-13 CA CA002344300A patent/CA2344300A1/en not_active Abandoned
- 1999-09-13 NZ NZ510209A patent/NZ510209A/en unknown
- 1999-09-13 EP EP99948210A patent/EP1113801A4/en not_active Withdrawn
- 1999-09-13 BR BR9913831-0A patent/BR9913831A/pt not_active IP Right Cessation
- 1999-09-15 CO CO99058376A patent/CO5130026A1/es unknown
- 1999-09-15 CO CO99058374A patent/CO5130025A1/es unknown
- 1999-09-16 UY UY25713A patent/UY25713A1/es unknown
- 1999-09-16 UY UY25714A patent/UY25714A1/es unknown
- 1999-09-17 PE PE1999000944A patent/PE20001047A1/es not_active Application Discontinuation
- 1999-09-17 PE PE1999000943A patent/PE20001056A1/es not_active Application Discontinuation
2001
- 2001-03-16 LT LT2001023A patent/LT4870B/lt not_active IP Right Cessation
- 2001-03-16 LT LT2001022A patent/LT4871B/lt not_active IP Right Cessation
- 2001-03-16 NO NO20011351A patent/NO20011351L/no unknown
- 2001-03-16 NO NO20011352A patent/NO20011352L/no not_active Application Discontinuation
- 2001-04-10 BG BG105432A patent/BG105432A/xx unknown
- 2001-04-10 BG BG105431A patent/BG105431A/xx unknown
- 2001-04-12 LV LV010057A patent/LV12686B/xx unknown
- 2001-04-12 LV LV010058A patent/LV12687B/xx unknown
- 2001-07-13 US US09/905,235 patent/US20020035064A1/en not_active Abandoned
2002
- 2002-09-16 ZA ZA200207433A patent/ZA200207433B/en unknown
- 2002-09-16 ZA ZA200207430A patent/ZA200207430B/en unknown

Also Published As

Publication number	Publication date
JP2002524518A (ja)	2002-08-06
CZ2001965A3 (cs)	2002-02-13
EP1121129A1 (en)	2001-08-08
PL346660A1 (en)	2002-02-25
BG105431A (en)	2001-12-29
KR20010079842A (ko)	2001-08-22
CA2344300A1 (en)	2000-03-23
NZ510207A (en)	2003-08-29
LV12687A (en)	2001-07-20
ZA200207433B (en)	2003-10-27
CO5130025A1 (es)	2002-02-27
HUP0104240A2 (hu)	2002-03-28
LT4870B (lt)	2001-12-27
WO2000015229A1 (en)	2000-03-23
UY25713A1 (es)	2001-08-27
ID27833A (id)	2001-04-26
WO2000015230A1 (en)	2000-03-23
LV12686A (en)	2001-07-20
BG105432A (en)	2001-12-29
TR200100773T2 (tr)	2001-07-23
ATE406898T1 (de)	2008-09-15
CN1317970A (zh)	2001-10-17
EP1121129A4 (en)	2002-10-16
PL346661A1 (en)	2002-02-25
US20020035064A1 (en)	2002-03-21
JP2002524517A (ja)	2002-08-06
EE200100154A (et)	2002-12-16
LT2001022A (en)	2001-08-27
AU6143799A (en)	2000-04-03
NO20011351D0 (no)	2001-03-16
LT2001023A (en)	2001-08-27
NO20011352D0 (no)	2001-03-16
PE20001047A1 (es)	2000-12-24
LV12687B (lv)	2001-10-20
AU755563B2 (en)	2002-12-12
CZ2001964A3 (cs)	2002-01-16
EE200100155A (et)	2002-08-15
AU754488B2 (en)	2002-11-14
GEP20033045B (en)	2003-08-25
CA2344309A1 (en)	2000-03-23
EP1113801A4 (en)	2002-10-02
NO20011351L (no)	2001-05-11
ZA200207430B (en)	2003-09-16
SK3202001A3 (en)	2002-04-04
ES2311306T3 (es)	2009-02-01
ID28450A (id)	2001-05-24
EP1121129B1 (en)	2008-09-03
IL141785A0 (en)	2002-03-10
AU6387799A (en)	2000-04-03
GEP20033044B (en)	2003-08-25
PE20001056A1 (es)	2000-12-24
CO5130026A1 (es)	2002-02-27
CN1319012A (zh)	2001-10-24
BR9913833A (pt)	2001-05-29
HUP0104108A2 (hu)	2002-03-28
IL141786A0 (en)	2002-03-10
KR20010075150A (ko)	2001-08-09
TR200100774T2 (tr)	2001-12-21
EP1113801A1 (en)	2001-07-11
NO20011352L (no)	2001-05-11
DE69939481D1 (de)	2008-10-16
NZ510209A (en)	2003-07-25
BR9913831A (pt)	2001-05-29
UY25714A1 (es)	2001-08-27
LT4871B (lt)	2001-12-27
LV12686B (lv)	2001-10-20

Publication	Publication Date	Title
EE04356B1 (et)	2004-10-15	aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
EA200100002A1 (ru)	2001-08-27	Бензотиепины, обладающие активностью ингибиторов перемещения желчных кислот в подвздошной кишке и поглощения таурхолата
DE69929996D1 (de)	2006-04-27	Pharmazeutisches mittel zur behandlung von diabetes
RS50091B (sr)	2009-01-22	Upotreba retigabina u lečenju neuropatskog bola
DE60035575D1 (de)	2007-08-30	Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie
BR9406178A (pt)	1996-02-06	Composição de amino-açucar e glicosaminoglicano para o tratamento e restauração de tecido conectivo
BR0110506A (pt)	2003-04-01	Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
AU2002231095A1 (en)	2002-09-05	Method and composition for the treatment of diabetic neuropathy
DE69801661D1 (de)	2001-10-18	Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten
ES2088128T3 (es)	1996-08-01	Aminosulfonilureas inhibidoras de acat.
MX9805290A (es)	1998-10-31	Utilizacion de inhibidores de la actividad del acido retinoico para tratar las pieles sensibles y/o los daños agudos inducidos por las radiaciones ultravioleta.
NO996206L (no)	2000-02-15	Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
AU8851298A (en)	1999-03-22	L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
ES2190581T3 (es)	2003-08-01	2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
MY140504A (en)	2009-12-31	Statin-mmp inhibitor combinations
NO963989L (no)	1996-11-22	Hypokolesterolemiske-, antiatherosklerotiske- og hypotriglyceridemiske mercaptoacetylamidderivater
IL125660A0 (en)	1999-04-11	Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture
BR0112460A (pt)	2003-07-22	Método para tratamento de sépsis
TH48054A3 (th)	2001-11-05	วิธีการรักษาอาธีโรสเคลอโรซิส โดยใช้ตัวยับยั้ง aP2 และสิ่งผสมรวม
ATE292970T1 (de)	2005-04-15	Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
BR9502960A (pt)	1997-09-23	Composto de espirostanil-glicósido método para o tratamento de hipercolesterolomia composição farmacêutica e método para o tratamento de aterosclerose

Legal Events

Date	Code	Title	Description
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2005-06-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20040913